Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

NCT07584889 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

B Cell Lymphoma
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions

COMBINATION_PRODUCT: CAR-T cell

Sponsor

Shenzhen University General Hospital